Related Experiment Video
Updated: Jun 1, 2026

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels
Published on: May 26, 2023
Infective endocarditis caused by Moraxella nonliquefaciens in a percutaneous aortic valve replacement
Isma Rafiq1, Hari Parthasarathy1, Catherine Tremlett2
1Department Cardiology, Norfolk & Norwich University NHS Hospital.
Abstract:
First case of infective endocarditis on a percutaneous aortic valve replacement due to Moraxalla nonliquefaciens in 64 year old woman. It was successfully treated medically with antibiotics. She had not suitable for surgical aortic valve replacement due to 3 sternotomies for thymoma resection and subsequent radiotherapy with blocked major thoracic veins. Due to her azathioprine immunosuppresion (myasthenia) she may have been at increased endocarditis risk. We suggest prophylactic antibiotics at implant for this group in future.
Insights
This is the first reported case of infective endocarditis caused by Moraxella nonliquefaciens following a percutaneous aortic valve replacement. Medical treatment with antibiotics proved successful for this high-risk patient.
Area of Science:
- Cardiology
- Infectious Diseases
- Medical Device Infections
Background:
- Infective endocarditis (IE) is a serious complication following cardiac procedures.
- Percutaneous aortic valve replacement (PAVR) is an alternative to surgical AVR, particularly for high-risk patients.
- Moraxella species are uncommon causes of IE, especially in the context of prosthetic valves.
Observation:
- A 64-year-old woman developed IE due to Moraxella nonliquefaciens after undergoing PAVR.
- The patient had a complex medical history including multiple sternotomies and radiotherapy, rendering her unsuitable for surgical AVR.
- She was also on azathioprine immunosuppression for myasthenia gravis, potentially increasing her risk for IE.
Findings:
- The patient's IE was successfully treated with a course of antibiotics.
- This case represents the first documented instance of Moraxella nonliquefaciens causing IE on a PAVR prosthesis.
- The clinical course highlights the challenges in managing IE in patients with significant comorbidities and prior thoracic interventions.
Implications:
- This case underscores the importance of considering unusual pathogens in prosthetic valve endocarditis.
- The successful medical management suggests that antibiotics alone may be sufficient in select cases, avoiding high-risk surgery.
- Prophylactic antibiotic administration at the time of PAVR implantation may be warranted for patients with similar risk factors, such as prior sternotomies and immunosuppression.
Related Concept Videos
Endocarditis I: Introduction
Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Mitral Stenosis I: Introduction
Mitral Valve Prolapse I: Introduction

